Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

114 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, Milhem M, Markovic SN, Bowles T, Hamid O, Hernandez-Aya L, Claveau J, Jang S, Philips P, Holtan SG, Shaheen MF, Curti B, Schmidt W, Butler MO, Paramo J, Lutzky J, Padmanabhan A, Thomas S, Milton D, Pecora A, Sato T, Hsueh E, Badarinath S, Keech J, Kalmadi S, Kumar P, Weber R, Levine E, Berger A, Bar A, Beck JT, Travers JB, Mihalcioiu C, Gastman B, Beitsch P, Rapisuwon S, Glaspy J, McCarron EC, Gupta V, Behl D, Blumenstein B, Peterkin JJ. Slingluff CL, et al. Among authors: blumenstein b. J Immunother Cancer. 2021 Oct;9(10):e003272. doi: 10.1136/jitc-2021-003272. J Immunother Cancer. 2021. PMID: 34599031 Free PMC article.
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival.
Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, Tjalma WAA, Denys H, van Poelgeest MIE, Nijman HW, Reyners AKL, Velu T, Goffin F, Lalisang RI, Loof NM, Boekestijn S, Krebber WJ, Hooftman L, Visscher S, Blumenstein BA, Stead RB, Gerritsen W, van der Burg SH. Melief CJM, et al. Among authors: blumenstein ba. Sci Transl Med. 2020 Mar 18;12(535):eaaz8235. doi: 10.1126/scitranslmed.aaz8235. Sci Transl Med. 2020. PMID: 32188726
Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein B, Saad F, Luo J, de Bono JS. Taplin ME, et al. Among authors: blumenstein b. Eur Urol. 2019 Dec;76(6):843-851. doi: 10.1016/j.eururo.2019.08.034. Epub 2019 Sep 18. Eur Urol. 2019. PMID: 31542304 Clinical Trial.
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K. Beer TM, et al. Among authors: blumenstein b. Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9. Lancet Oncol. 2017. PMID: 29033099 Clinical Trial.
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.
Bellmunt J, Eigl BJ, Senkus E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar SS, Sternberg CN, Retz M, Pal S, Blumenstein B, Jacobs C, Stewart PS, Petrylak DP. Bellmunt J, et al. Among authors: blumenstein b. Ann Oncol. 2017 Oct 1;28(10):2481-2488. doi: 10.1093/annonc/mdx400. Ann Oncol. 2017. PMID: 28961845 Free article. Clinical Trial.
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Chi KN, Higano CS, Blumenstein B, Ferrero JM, Reeves J, Feyerabend S, Gravis G, Merseburger AS, Stenzl A, Bergman AM, Mukherjee SD, Zalewski P, Saad F, Jacobs C, Gleave M, de Bono JS. Chi KN, et al. Among authors: blumenstein b. Lancet Oncol. 2017 Apr;18(4):473-485. doi: 10.1016/S1470-2045(17)30168-7. Epub 2017 Mar 8. Lancet Oncol. 2017. PMID: 28283282 Clinical Trial.
Amyloidosis presenting as a colonic mass. A case report.
Dakhoul L, Keshmiri H, Werdi A, Blumenstein BJ. Dakhoul L, et al. Among authors: blumenstein bj. Int J Colorectal Dis. 2015 Feb;30(2):291. doi: 10.1007/s00384-014-1988-6. Epub 2014 Aug 21. Int J Colorectal Dis. 2015. PMID: 25139368 No abstract available.
Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.
Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castaños-Vélez E, Blumenstein BA, Rösch T, Osborn N, Snover D, Day RW, Ransohoff DF; PRESEPT Clinical Study Steering Committee, Investigators and Study Team. Church TR, et al. Among authors: blumenstein ba. Gut. 2014 Feb;63(2):317-25. doi: 10.1136/gutjnl-2012-304149. Epub 2013 Feb 13. Gut. 2014. PMID: 23408352 Free PMC article.
114 results